Form 4: Immuneering CBO Acquires Shares Under 10b5-1 Plan

Immuneering Corp's Chief Business Officer, Harold Brakewood, acquired 5,250 shares of Class A Common Stock at $4.76 per share on January 16, 2026, through a pre-arranged trading plan.

Summary

• Harold Brakewood, Chief Business Officer of Immuneering Corp (IMRX), acquired 5,250 shares of Class A Common Stock.
• The transaction occurred on January 16, 2026, at a price of $4.76 per share.
• Following this purchase, Brakewood directly beneficially owns 11,050 shares of Class A Common Stock.
• The acquisition was made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.

Sentiment

Score: 7

Explanation: An insider purchase, particularly by a C-level executive, generally indicates confidence in the company's future. The 10b5-1 plan suggests a pre-planned investment strategy rather than a reactive trade, which is a neutral to slightly positive factor.

Positives

• An insider, the Chief Business Officer, increased their direct ownership in the company, which can signal confidence in future performance.
• The purchase was made under a Rule 10b5-1 plan, indicating a pre-scheduled transaction rather than an immediate reaction to recent news.

Future Outlook

This filing does not contain forward-looking statements or guidance, as it reports a past insider transaction.

Industry Context

Insider purchases, especially by high-ranking officers like a Chief Business Officer, are often viewed by the market as a positive signal, suggesting management's belief in the company's prospects within the biotechnology or pharmaceutical industry.

Stakeholder Impact

• Shareholders may view the insider purchase as a positive signal of management's confidence in the company's valuation and future prospects.

Key Dates

Recommendation

While an insider purchase by a Chief Business Officer is generally a positive signal, indicating management's confidence, this single transaction under a 10b5-1 plan does not provide enough fundamental information to warrant a 'buy' recommendation. It reinforces a 'hold' position for existing investors, suggesting continued confidence from within, but new investors would need to conduct further due diligence on the company's broader financial health and strategic outlook.

Keywords

Immuneering Corp, IMRX, Insider Trading, Form 4, Stock Purchase, Harold Brakewood, Chief Business Officer, 10b5-1 Plan, Equity Acquisition